TIVA, or total intravenous anesthesia, is a technique for general anesthesia that uses only drugs delivered through an IV line, with no inhaled gases. Instead of breathing in anesthetic vapor through a mask or breathing tube, you receive a continuous stream of medications directly into your bloodstream. The two most commonly used drugs are propofol (a sedative) and remifentanil (a fast-acting pain reliever), often combined with other agents to keep you unconscious, pain-free, and still during surgery.
How TIVA Differs From Gas Anesthesia
In traditional general anesthesia, you breathe in a vaporized anesthetic agent (like sevoflurane or desflurane) mixed with oxygen. These gases enter your lungs, cross into your blood, and reach your brain to keep you unconscious. With TIVA, that entire process is bypassed. Medications go straight from the IV into your circulation, and anesthesiologists control the depth of your anesthesia by adjusting infusion rates rather than turning a dial on a vaporizer.
TIVA relies on a combination of drug classes working together: one to keep you unconscious, one to block pain, and sometimes a muscle relaxant. This layered approach lets each drug do its specific job at a lower dose, reducing side effects from any single agent.
How the Drugs Are Delivered
Getting the right amount of anesthetic into your system at every moment is the central challenge of TIVA. Unlike gas anesthesia, where the concentration of vapor can be measured in real time from your exhaled breath, IV drugs don’t offer that same instant feedback. To solve this, anesthesiologists use computerized infusion pumps guided by pharmacokinetic models, a system called target-controlled infusion (TCI).
TCI pumps use mathematical models of how your body absorbs, distributes, and eliminates a drug. The two most widely used models for propofol are the Marsh model and the Schnider model. The Marsh model adjusts dosing based primarily on your body weight, treating patients of the same weight similarly regardless of age. The Schnider model is more nuanced, factoring in your age, gender, height, and lean body mass to fine-tune delivery. Your anesthesiologist sets a target drug concentration, and the pump continuously recalculates the infusion rate to maintain it, slowing down as the drug accumulates in your tissues and speeding up when levels drop.
These models account for the fact that anesthetic drugs don’t just stay in your blood. They redistribute into muscle tissue quickly and into fat tissue more slowly, which means the pump has to anticipate where the drug is going, not just where it is right now.
Brain Monitoring During TIVA
Because there’s no exhaled gas concentration to confirm the anesthetic is working, monitoring brain activity becomes especially important during TIVA. Processed EEG monitors (devices that read electrical activity from your brain through sensors on your forehead) give the anesthesiologist a numerical readout of how deeply you’re sedated.
The Association of Anaesthetists recommends using processed EEG monitoring whenever TIVA is combined with a muscle relaxant. Muscle relaxants prevent you from moving, which means the usual physical signs that someone is too light on anesthesia (like flinching or tensing) are masked. Without brain monitoring in that scenario, there’s a small but real risk of awareness during surgery. When TIVA is administered outside the operating room, such as in an MRI suite or during patient transport, the same monitoring standards apply, though MRI-compatible brain monitors aren’t yet widely available.
Less Nausea After Surgery
One of the clearest advantages of TIVA is a significant reduction in postoperative nausea and vomiting, one of the most common and most dreaded side effects of general anesthesia. In a randomized trial comparing the two approaches for abdominal surgery, 50.9% of patients who received inhaled anesthesia developed nausea or vomiting afterward, compared to just 17.3% in the TIVA group. The need for anti-nausea medication was also cut by more than half: 24.5% of the inhalation group needed rescue treatment versus 9.6% of the TIVA group.
This makes TIVA a particularly strong option if you’re already at higher risk for postoperative nausea, including women, non-smokers, people with a history of motion sickness, and anyone undergoing procedures known to trigger it (like gynecological, abdominal, or ear surgeries).
Faster Recovery for Some Patients
Recovery speed depends partly on your health profile. For patients with obstructive sleep apnea (OSA), TIVA can make a meaningful difference. One study found that OSA patients recovered about 41 minutes faster after TIVA compared to sevoflurane gas anesthesia. Even among patients without sleep apnea, TIVA shortened recovery room stays by 18 to 27 minutes depending on the type of surgery.
This faster wake-up happens because propofol is rapidly cleared from the body once the infusion stops, while inhaled agents need to be “washed out” of the lungs and fatty tissues. Remifentanil, the pain reliever most commonly paired with propofol, breaks down in the blood within minutes, which means its sedating effects wear off almost immediately.
When TIVA Is Preferred or Required
Certain situations make TIVA the better choice, or the only safe one. The most clear-cut is malignant hyperthermia susceptibility, a rare genetic condition where inhaled anesthetics can trigger a life-threatening reaction of uncontrolled muscle metabolism and dangerously high body temperature. For these patients, volatile gases are completely off the table, and TIVA is the standard approach.
TIVA is also preferred for neurosurgery and procedures that involve monitoring nerve signals during the operation, since propofol interferes less with those readings than inhaled agents do. For obese patients undergoing high-risk surgeries (abdominal, gynecological, or procedures involving the airway), TIVA may offer a safer profile, especially when paired with anti-nausea measures. It’s also the practical choice when surgery happens outside a traditional operating room, such as in radiology suites or endoscopy units, where anesthetic gas delivery and scavenging systems may not be available.
During the COVID-19 pandemic, TIVA gained further traction because it avoids the aerosolization risks associated with gas anesthesia circuits, reducing potential viral exposure for operating room staff.
Cost Considerations
TIVA does tend to cost more upfront. The IV drugs and specialized infusion equipment carry higher pharmacy and operating room costs compared to volatile agents. One study of sleep apnea surgeries found TIVA added roughly $286 in total costs for nasal procedures. However, those added expenses were partially or fully offset by lower supply costs and shorter recovery room stays. For certain procedures, the savings in recovery time (and the associated staffing and room costs) brought the overall price close to even.
The cost equation also shifts depending on surgery length. Longer procedures tend to favor TIVA financially, since the hourly cost of IV drugs increases slowly while volatile agent costs accumulate more steeply over time.
Environmental Footprint
Inhaled anesthetic gases are potent greenhouse gases. Sevoflurane and desflurane escape into the atmosphere after use and trap heat far more effectively than carbon dioxide. TIVA sidesteps this entirely, since propofol and other IV drugs produce no direct atmospheric emissions.
The trade-off is that TIVA generates more physical waste: syringes, tubing, and single-use pump components. A modeling study found that for procedures shorter than about 22 minutes, the plastic waste from TIVA actually gives it a larger carbon footprint than sevoflurane. But beyond that point, TIVA pulls ahead. After 44 minutes, every sevoflurane scenario produced a higher carbon footprint than any TIVA scenario. At the one-hour mark, the moderate TIVA setup added only 0.04 to 0.60 kg of CO₂ equivalent per hour, compared to 4.01 kg for sevoflurane. By six hours of surgery, sevoflurane accounted for 99.5% of the total carbon footprint of inhalation anesthesia.